• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by SOPHiA GENETICS SA

    7/3/25 1:24:16 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SOPH alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0002006414
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    SOPHIA GENETICS SA
    SEC File Number
    001-40627
    Address of Issuer
    La Piece 12 ch-1180
    Rolle
    SWITZERLAND
    00000
    Phone
    41216941060
    Name of Person for Whose Account the Securities are To Be Sold
    DAAN GUIDO MARIA VAN WELL
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    627919088.166668708507/03/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common07/02/2025Restricted Stock UnitsIssuerCheckbox not checked627907/02/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common06/23/2025117354.28
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common06/20/20256852026.50
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common05/23/2025118338.80
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common05/19/20256851965.81
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common04/23/2025117354.70
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common04/21/20256841859.80
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common04/09/202523706560.16
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common04/08/202518695155.64
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common04/07/202518144858.62
    10b5-1 Sales for DAAN GUIDO MARIA VAN WELL
    La Piece 12 ch-1180
    Rolle � V8 � 00000
    Common04/04/202515494253.09

    144: Remarks and Signature

    Remarks
    The securities to be sold were or will be acquired upon the vesting of restricted stock units during the period of 07/02/2025 through 09/18/2025.
    Date of Notice
    07/03/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    09/09/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daan Guido Maria Van Well

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SOPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOPH

    DatePrice TargetRatingAnalyst
    12/18/2024$11.00Buy
    Craig Hallum
    8/7/2024$10.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$6.00Buy
    Guggenheim
    11/29/2023$8.00Outperform
    RBC Capital Mkts
    7/5/2023$10.00Overweight
    JP Morgan
    1/3/2023$6.00Buy
    BTIG Research
    11/23/2022$2.00Neutral
    Credit Suisse
    2/15/2022$23.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $SOPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SOPHiA GENETICS Reports Second Quarter 2025 Results

    BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue was $18.3 million, up 16% year-over-yearGross margin was 67.0% on a reported basis and 74.4% on an adjusted basis, up from 68.2% reported and 73.2% adjusted in the prior year periodIFRS net loss increased 48% year-over-year to $22.4 million (or 23% excluding foreign exchange impact); Adjusted EBITDA

    8/5/25 6:45:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

    BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (NASDAQ:AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer.

    8/5/25 6:40:00 AM ET
    $AZN
    $SOPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025

    BOSTON and ROLLE, Switzerland, July 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter 2025 before U.S. markets open on Tuesday, August 5, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will

    7/22/25 8:00:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SOPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on SOPHiA GENETICS SA with a new price target

    Craig Hallum initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $11.00

    12/18/24 7:54:16 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS SA downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded SOPHiA GENETICS SA from Overweight to Equal-Weight and set a new price target of $5.00 from $10.00 previously

    8/7/24 11:39:17 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on SOPHiA GENETICS SA with a new price target

    Guggenheim initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $6.00

    6/27/24 7:51:58 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SOPH
    SEC Filings

    View All

    SEC Form EFFECT filed by SOPHiA GENETICS SA

    EFFECT - SOPHiA GENETICS SA (0001840706) (Filer)

    8/18/25 12:15:18 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by SOPHiA GENETICS SA

    EFFECT - SOPHiA GENETICS SA (0001840706) (Filer)

    8/18/25 12:15:19 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by SOPHiA GENETICS SA

    424B5 - SOPHiA GENETICS SA (0001840706) (Filer)

    8/15/25 4:44:18 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SOPH
    Leadership Updates

    Live Leadership Updates

    View All

    SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

    BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

    11/5/24 6:32:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care

    New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

    5/30/24 12:19:00 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

    Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023. An award-winning powerhouse in the global technology

    5/31/23 9:12:00 AM ET
    $SOPH
    $XYL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Fluid Controls
    Industrials

    $SOPH
    Financials

    Live finance-specific insights

    View All

    SOPHiA GENETICS Reports Second Quarter 2025 Results

    BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue was $18.3 million, up 16% year-over-yearGross margin was 67.0% on a reported basis and 74.4% on an adjusted basis, up from 68.2% reported and 73.2% adjusted in the prior year periodIFRS net loss increased 48% year-over-year to $22.4 million (or 23% excluding foreign exchange impact); Adjusted EBITDA

    8/5/25 6:45:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025

    BOSTON and ROLLE, Switzerland, July 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter 2025 before U.S. markets open on Tuesday, August 5, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will

    7/22/25 8:00:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SOPHiA GENETICS Reports First Quarter 2025 Results

    BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha

    5/6/25 6:45:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SOPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SOPHiA GENETICS SA

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    11/13/24 3:31:21 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    2/20/24 4:55:59 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

    SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

    2/14/24 11:23:25 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care